PH12018501375A1 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors - Google Patents

Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Info

Publication number: PH12018501375A1
Authority: PH; Philippines
Prior art keywords: azabicyclo; hexanes; substituted; ketohexokinase inhibitors; ketohexokinase
Prior art date: 2015-12-29

Application number

PH12018501375A

Other languages

English (en)

Inventor

Matthew Dowling

Dilinie Fernando

Kentaro Futatsugi

Kim Huard

Thomas Victor Magee

Brian Raymer

Andre Shavnya

Aaron Smith

Benjamin Thuma

Andy Tsai

Meihua Tu

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-29

Filing date

2018-06-26

Publication date

2019-02-11

2018-06-26 Application filed by Pfizer filed Critical Pfizer

2019-02-11 Publication of PH12018501375A1 publication Critical patent/PH12018501375A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)

PH12018501375A 2015-12-29 2018-06-26 Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors PH12018501375A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562272598P	2015-12-29	2015-12-29
US201662423549P	2016-11-17	2016-11-17
PCT/IB2016/057728 WO2017115205A1 (en)	2015-12-29	2016-12-16	Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Publications (1)

Publication Number	Publication Date
PH12018501375A1 true PH12018501375A1 (en)	2019-02-11

Family

ID=57755415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12018501375A PH12018501375A1 (en)	2015-12-29	2018-06-26	Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Country Status (38)

Country	Link
US (6)	US9809579B2 (es)
EP (1)	EP3397631B1 (es)
JP (1)	JP6503515B2 (es)
KR (1)	KR102073048B1 (es)
CN (1)	CN108473469B (es)
AU (1)	AU2016380920B2 (es)
CA (1)	CA2952466C (es)
CL (1)	CL2018001667A1 (es)
CO (1)	CO2018006714A2 (es)
CU (1)	CU24540B1 (es)
CY (1)	CY1124389T1 (es)
DK (1)	DK3397631T3 (es)
EC (1)	ECSP18048517A (es)
ES (1)	ES2871251T3 (es)
GE (1)	GEP20207147B (es)
HR (1)	HRP20210769T1 (es)
HU (1)	HUE054380T2 (es)
IL (1)	IL260330B (es)
LT (1)	LT3397631T (es)
MA (1)	MA43518B1 (es)
MD (1)	MD3397631T2 (es)
MX (1)	MX376072B (es)
NI (1)	NI201800072A (es)
PE (1)	PE20181289A1 (es)
PH (1)	PH12018501375A1 (es)
PL (1)	PL3397631T3 (es)
PT (1)	PT3397631T (es)
RS (1)	RS61896B1 (es)
RU (1)	RU2696269C1 (es)
SG (1)	SG11201804363UA (es)
SI (1)	SI3397631T1 (es)
SV (1)	SV2018005709A (es)
TN (1)	TN2018000198A1 (es)
TW (1)	TWI653232B (es)
UA (1)	UA121271C2 (es)
UY (1)	UY37051A (es)
WO (1)	WO2017115205A1 (es)
ZA (1)	ZA201803449B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108473469B (zh) *	2015-12-29	2020-11-03	辉瑞公司	作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
PE20190607A1 (es)	2016-09-02	2019-04-23	Ironwood Pharmaceuticals Inc	Estimuladores de sgc
US10558874B1 (en)	2017-01-19	2020-02-11	State Farm Mutual Automobile Insurance Company	Apparatuses, systems and methods for generation and transmission of vehicle operation mode data
CN109316601B (zh) *	2017-07-31	2021-11-09	武汉朗来科技发展有限公司	药物组合物及其用途
US10934279B2 (en)	2018-06-13	2021-03-02	Pfizer Inc.	GLP-1 receptor agonists and uses thereof
BR112021003039A2 (pt) *	2018-08-31	2021-05-18	Pfizer Inc.	combinações para o tratamento de nash/nafld e doenças relacionadas
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
KR102558308B1 (ko) *	2018-09-27	2023-07-24	주식회사 엘지화학	3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
WO2020156445A1 (zh) *	2019-01-29	2020-08-06	山东轩竹医药科技有限公司	己酮糖激酶抑制剂及其用途
WO2020215034A1 (en) *	2019-04-19	2020-10-22	The Regents Of The University Of California	An ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2020234726A1 (en)	2019-05-20	2020-11-26	Pfizer Inc.	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN111978296A (zh) *	2019-05-22	2020-11-24	山东轩竹医药科技有限公司	己酮糖激酶抑制剂及其用途
MX2021014441A (es)	2019-05-31	2022-01-06	Ikena Oncology Inc	Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
TWI750685B (zh) *	2019-06-17	2021-12-21	美商美國禮來大藥廠	二取代吡唑化合物
TWI809334B (zh)	2019-12-10	2023-07-21	美商輝瑞股份有限公司	２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
JP7403661B2 (ja) *	2019-12-24	2023-12-22	杭州中美華東製薬有限公司	Ｋｈｋ阻害効果を有する化合物
WO2021129817A1 (zh) *	2019-12-25	2021-07-01	南京明德新药研发有限公司	具有果糖激酶(khk)抑制作用的嘧啶类化合物
GB202001856D0 (en) *	2020-02-11	2020-03-25	Inorbit Therapeutics Ab	Compounds useful in inhibiting ketohexokinase and methods of making and using the same
WO2021162943A1 (en)	2020-02-13	2021-08-19	Eli Lilly And Company	2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds
JP2021134211A (ja)	2020-02-24	2021-09-13	ファイザー・インク	Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US20230201185A1 (en)	2020-03-27	2023-06-29	Pfizer Inc.	Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR102614659B1 (ko) *	2020-04-20	2023-12-19	주식회사 엘지화학	3-아자바이사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
CN111423420A (zh) *	2020-04-30	2020-07-17	广州博济医药生物技术股份有限公司	作为己酮糖激酶抑制剂的并环化合物
CN113754640B (zh) *	2020-06-03	2023-02-14	山东轩竹医药科技有限公司	氘代的己酮糖激酶抑制剂及其用途
WO2022022476A1 (zh) *	2020-07-28	2022-02-03	山东轩竹医药科技有限公司	己酮糖激酶抑制剂的盐、晶型及其用途
IL301285A (en)	2020-09-10	2023-05-01	Precirix N V	Antibody fragment against fap
CN114181198B (zh) *	2020-09-15	2025-07-15	山东轩竹医药科技有限公司	嘧啶衍生物类己酮糖激酶抑制剂及其用途
WO2022135390A1 (zh) *	2020-12-25	2022-06-30	四川海思科制药有限公司	己酮糖激酶抑制剂及其用途
KR20230158542A (ko)	2021-03-29	2023-11-20	길리애드 사이언시즈, 인코포레이티드	Khk 억제제
KR20220136939A (ko)	2021-04-01	2022-10-11	주식회사 엘지화학	옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
WO2022262841A1 (zh) *	2021-06-17	2022-12-22	杭州中美华东制药有限公司	一种螺环化合物的盐型、晶型及其制备方法
KR20240054335A (ko)	2021-08-31	2024-04-25	화이자 인코포레이티드	2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일｝피페리딘-1-일)메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카르복실산,1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
WO2023061492A1 (zh) *	2021-10-14	2023-04-20	华领医药技术（上海）有限公司	2-氧代-3-氮杂双环[3.1.0]己烷衍生物
WO2023111817A1 (en)	2021-12-17	2023-06-22	Pfizer Inc.	Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
KR20230098069A (ko) *	2021-12-24	2023-07-03	주식회사 엘지화학	(s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물
CN114315494B (zh) *	2021-12-29	2023-09-22	苏州楚凯药业有限公司	一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法
WO2023151473A1 (zh) *	2022-02-09	2023-08-17	上海研健新药研发有限公司	一种khk抑制剂，其制备方法和应用
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
JP2025517625A (ja)	2022-05-02	2025-06-10	プレシリックス・ナームローゼ・ベンノートシヤープ	プレターゲティング
WO2023228023A1 (en)	2022-05-23	2023-11-30	Pfizer Inc.	Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
IL319392A (en)	2022-10-18	2025-05-01	Pfizer	Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
AR132416A1 (es)	2023-04-12	2025-06-25	Centennial Therapeutics Llc	Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa
AU2024278772A1 (en)	2023-05-31	2025-11-06	Centennial Therapeutics, Llc	Bicyclic compounds for ketohexokinase inhibition
WO2025099561A1 (en)	2023-11-07	2025-05-15	Pfizer Inc.	Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2025224648A1 (en)	2024-04-26	2025-10-30	Pfizer Inc.	Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4980350A (en)	1988-02-25	1990-12-25	Merck & Co., Inc.	Piperazinylalkylpyrimidines as hypoglycemic agents
DE4208254A1 (de)	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ES2318899T3 (es)	1998-07-06	2009-05-01	Bristol-Myers Squibb Company	Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
KR20030076716A (ko)	2001-02-28	2003-09-26	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
EP1478437B1 (en)	2002-02-27	2005-08-31	Pfizer Products Inc.	Acc inhibitors
DE602005015699D1 (de)	2004-05-12	2009-09-10	Pfizer Prod Inc	Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
JP4069159B2 (ja)	2004-05-25	2008-04-02	ファイザー・プロダクツ・インク	テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
PL2463283T3 (pl)	2006-04-20	2014-10-31	Pfizer Prod Inc	Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
US8933201B2 (en)	2006-06-07	2015-01-13	The Board Of Regents Of The University Of Oklahoma	Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008024902A2 (en)	2006-08-23	2008-02-28	University Of Florida Research Foundation, Inc.	Targeting of fructokinase as therapy for cardiovascular disease, metabolic syndrome, and renal disease
KR20090083956A (ko)	2006-11-29	2009-08-04	화이자 프로덕츠 인크.	스피로케톤 아세틸-ＣｏＡ 카르복실라제 억제제
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
JP5411867B2 (ja) *	2007-10-11	2014-02-12	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびそれらの使用
JP5435592B2 (ja)	2008-05-28	2014-03-05	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
JP2011521940A (ja)	2008-05-28	2011-07-28	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2729581A1 (en)	2008-07-29	2010-02-04	Pfizer Inc.	Fluorinated heteroaryls
CA2732618A1 (en) *	2008-07-30	2010-02-04	Ranbaxy Laboratories Limited	Pyrrole carboxylic acid derivatives as antibacterial agents
WO2010023594A1 (en)	2008-08-28	2010-03-04	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
UA99882C2 (uk)	2009-03-11	2012-10-10	Пфайзер Інк.	Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
CA2754685A1 (en)	2009-03-11	2010-09-16	Pfizer Inc.	Substituted indazole amides
EP2408780A2 (en)	2009-03-20	2012-01-25	Pfizer Inc.	3-oxa-7-azabicycloý3.3.1¨nonanes
NZ596213A (en) *	2009-04-08	2013-05-31	Actelion Pharmaceuticals Ltd	6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adenosine 5'-diphosphate (ADP) receptor antagonists
JP2012526097A (ja)	2009-05-08	2012-10-25	ファイザー・インク	Ｇｐｒ１１９調節因子
WO2010128414A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
KR20120061063A (ko)	2009-06-05	2012-06-12	화이자 인코포레이티드	Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
KR101686913B1 (ko) *	2009-08-13	2016-12-16	삼성전자주식회사	전자기기에서 이벤트 서비스 제공 방법 및 장치
CN102939283B (zh)	2010-04-22	2015-06-03	詹森药业有限公司	可用作己酮糖激酶抑制剂的吲唑化合物
EP2600897A2 (en) *	2010-08-06	2013-06-12	The Regents of the University of Colorado, A Body Corporate	Methods and compositions for the inhibition of fructokinase
CN102432598A (zh) *	2010-09-29	2012-05-02	江苏恒瑞医药股份有限公司	三环化合物、其制备方法及其在医药上的应用
US9371282B2 (en)	2013-05-17	2016-06-21	Centrexion Therapeutics Corporation	Somatostatin receptor subtype 4 (SSTR4) agonists
EP3960860A3 (en)	2014-02-11	2022-06-08	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
CN108473469B (zh) *	2015-12-29	2020-11-03	辉瑞公司	作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷

2016
- 2016-12-16 CN CN201680077234.3A patent/CN108473469B/zh active Active
- 2016-12-16 TN TNP/2018/000198A patent/TN2018000198A1/en unknown
- 2016-12-16 HU HUE16823054A patent/HUE054380T2/hu unknown
- 2016-12-16 KR KR1020187018089A patent/KR102073048B1/ko active Active
- 2016-12-16 GE GEAP201614820A patent/GEP20207147B/en unknown
- 2016-12-16 EP EP16823054.8A patent/EP3397631B1/en active Active
- 2016-12-16 AU AU2016380920A patent/AU2016380920B2/en active Active
- 2016-12-16 ES ES16823054T patent/ES2871251T3/es active Active
- 2016-12-16 SI SI201631206T patent/SI3397631T1/sl unknown
- 2016-12-16 MA MA43518A patent/MA43518B1/fr unknown
- 2016-12-16 US US15/381,295 patent/US9809579B2/en active Active
- 2016-12-16 JP JP2018533924A patent/JP6503515B2/ja active Active
- 2016-12-16 UA UAA201807242A patent/UA121271C2/uk unknown
- 2016-12-16 WO PCT/IB2016/057728 patent/WO2017115205A1/en not_active Ceased
- 2016-12-16 HR HRP20210769TT patent/HRP20210769T1/hr unknown
- 2016-12-16 SG SG11201804363UA patent/SG11201804363UA/en unknown
- 2016-12-16 RS RS20210654A patent/RS61896B1/sr unknown
- 2016-12-16 DK DK16823054.8T patent/DK3397631T3/da active
- 2016-12-16 PT PT168230548T patent/PT3397631T/pt unknown
- 2016-12-16 PE PE2018001204A patent/PE20181289A1/es unknown
- 2016-12-16 PL PL16823054T patent/PL3397631T3/pl unknown
- 2016-12-16 MD MDE20181083T patent/MD3397631T2/ro not_active IP Right Cessation
- 2016-12-16 CU CU2018000046A patent/CU24540B1/es unknown
- 2016-12-16 MX MX2018007755A patent/MX376072B/es active IP Right Grant
- 2016-12-16 RU RU2018123528A patent/RU2696269C1/ru active
- 2016-12-16 LT LTEP16823054.8T patent/LT3397631T/lt unknown
- 2016-12-22 CA CA2952466A patent/CA2952466C/en active Active
- 2016-12-27 UY UY0001037051A patent/UY37051A/es not_active Application Discontinuation
- 2016-12-28 TW TW105143483A patent/TWI653232B/zh active
2017
- 2017-10-11 US US15/729,885 patent/US10174007B2/en active Active
2018
- 2018-05-24 ZA ZA2018/03449A patent/ZA201803449B/en unknown
- 2018-06-13 SV SV2018005709A patent/SV2018005709A/es unknown
- 2018-06-19 CL CL2018001667A patent/CL2018001667A1/es unknown
- 2018-06-25 NI NI201800072A patent/NI201800072A/es unknown
- 2018-06-26 PH PH12018501375A patent/PH12018501375A1/en unknown
- 2018-06-27 CO CONC2018/0006714A patent/CO2018006714A2/es unknown
- 2018-06-27 EC ECSENADI201848517A patent/ECSP18048517A/es unknown
- 2018-06-28 IL IL260330A patent/IL260330B/en unknown
- 2018-12-06 US US16/211,283 patent/US20190106412A1/en not_active Abandoned
2020
- 2020-01-16 US US16/744,283 patent/US10787438B2/en active Active
- 2020-08-21 US US16/999,295 patent/US10988463B2/en active Active
2021
- 2021-03-23 US US17/209,780 patent/US11634410B2/en active Active
- 2021-05-06 CY CY20211100385T patent/CY1124389T1/el unknown

Also Published As

Publication number	Publication date
US20200377482A1 (en)	2020-12-03
KR102073048B1 (ko)	2020-02-04
BR112018012047A2 (pt)	2018-12-04
ES2871251T3 (es)	2021-10-28
HUE054380T2 (hu)	2021-09-28
US9809579B2 (en)	2017-11-07
US10787438B2 (en)	2020-09-29
CN108473469B (zh)	2020-11-03
US20200148669A1 (en)	2020-05-14
US20180037575A1 (en)	2018-02-08
EP3397631B1 (en)	2021-04-07
RU2696269C1 (ru)	2019-08-01
PT3397631T (pt)	2021-05-28
MX376072B (es)	2025-03-07
CL2018001667A1 (es)	2018-08-03
UA121271C2 (uk)	2020-04-27
HK1259073A1 (zh)	2019-11-22
HRP20210769T1 (hr)	2021-06-25
US10174007B2 (en)	2019-01-08
MD3397631T2 (ro)	2021-08-31
RS61896B1 (sr)	2021-06-30
TW201726659A (zh)	2017-08-01
CN108473469A (zh)	2018-08-31
SG11201804363UA (en)	2018-07-30
IL260330A (en)	2018-08-30
ECSP18048517A (es)	2018-07-31
KR20180083427A (ko)	2018-07-20
PE20181289A1 (es)	2018-08-07
IL260330B (en)	2021-07-29
US11634410B2 (en)	2023-04-25
AU2016380920A1 (en)	2018-06-14
CU20180046A7 (es)	2018-09-05
CA2952466C (en)	2025-07-08
US20210309644A1 (en)	2021-10-07
MX2018007755A (es)	2018-11-09
SV2018005709A (es)	2018-09-10
US20170183328A1 (en)	2017-06-29
TN2018000198A1 (en)	2019-10-04
TWI653232B (zh)	2019-03-11
CO2018006714A2 (es)	2018-07-10
US10988463B2 (en)	2021-04-27
LT3397631T (lt)	2021-06-10
CA2952466A1 (en)	2017-06-29
PL3397631T3 (pl)	2021-09-20
NI201800072A (es)	2018-11-22
CY1124389T1 (el)	2022-07-22
CU24540B1 (es)	2021-08-06
EP3397631A1 (en)	2018-11-07
JP6503515B2 (ja)	2019-04-17
SI3397631T1 (sl)	2022-01-31
ZA201803449B (en)	2019-02-27
UY37051A (es)	2017-07-31
AU2016380920B2 (en)	2019-10-31
MA43518B1 (fr)	2021-05-31
WO2017115205A1 (en)	2017-07-06
GEP20207147B (en)	2020-09-10
US20190106412A1 (en)	2019-04-11
JP2019500383A (ja)	2019-01-10
MA43518A (fr)	2018-11-07
DK3397631T3 (da)	2021-05-25

Publication	Publication Date	Title
PH12018501375A1 (en)	2019-02-11	Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
MX2021004479A (es)	2021-06-04	Agentes biologicos y su uso en plantas.
EP3097509A4 (en)	2017-09-20	Intercepting and supervising calls to transformed operations and objects
AU2015208932A8 (en)	2017-03-09	(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
MX2017003933A (es)	2017-06-30	Metodos de tratamiento de la enfermedad hepatica.
MX2020002544A (es)	2020-07-20	Sales de glicopirrolato.
EA201692043A1 (ru)	2017-02-28	Лекарственная форма иммунодепрессанта
MX2016012053A (es)	2017-04-27	Procedimiento de compuesto antifungico.
PH12016502002B1 (en)	2021-01-29	Novel bacteriophage and composition comprising same
SA517390034B1 (ar)	2021-12-23	مشتقات الكربوكساميدو بيروليدين وطرق تحضيرها واستخدامها
PH12017501022B1 (en)	2022-02-16	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
EP3094798A4 (en)	2017-08-30	Padlock cylinder retention
MY180179A (en)	2020-11-24	A novel modified ornithine decarboxylase protein and a use thereof
WO2014146111A3 (en)	2014-10-16	Analgesic compounds and methods of use
MX2015016603A (es)	2016-07-28	Composiciones de corticosteroides.
MX2017006712A (es)	2017-09-01	Inhibidor de produccion de metaloproteinasa de matriz.
GB2543709A (en)	2017-04-26	Pharmaceutical agent
EP3240540A4 (en)	2018-11-21	Hdac1,2 inhibitors and methods of using the same
MX2015017198A (es)	2016-10-14	Matriz.
EA201800348A1 (ru)	2019-03-29	Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы
IN2013MU03310A (es)	2015-07-31
PH12014000104A1 (en)	2015-09-28	Therapeutic methods and compositions for treating diabetes
UA106905U (uk)	2016-05-10	Фармацевтична композиція
UA93017U (uk)	2014-09-10	Препарат "нановулін-врх"